Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQUA: Amlitelimab in Moderate-to-Severe Atopic Dermatitis
NCT06241118Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Validated Investigator Global Assessment scale for Atopic Dermatitis of 0 or 1 at 36 weeks and Eczema Area and Severity Index 75% reduction at 36 weeks. Started Feb 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06241118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241118.